Across TCGA pan-cancer cohorts, SDCBP2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SDCBP2 data layer compared with 17 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in rectum adenocarcinoma (READ), where higher SDCBP2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SDCBP2 expression acts as an unfavorable survival marker.
READ, STAD, and UCEC are the cancer types where SDCBP2 Mutation most reproducibly stratifies survival.